-
公开(公告)号：US20210071140A1
公开(公告)日：2021-03-11
申请号：US16951310
申请日：2020-11-18
发明人： Micah BENSON , Jason MERKIN , Gregory V. KRYUKOV , Solomon Martin SHENKER , Michael SCHLABACH , Noah TUBO , James Martin KABERNA, II
IPC分类号： C12N5/0783 , A61K35/17 , A61P35/00 , A61P35/04 , C12N9/22 , C12N15/113 , C12N15/11 , C07K16/28 , C07K16/32 , C07K14/705 , C07K14/725
摘要： The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.
-
公开(公告)号：US20200181610A1
公开(公告)日：2020-06-11
申请号：US16791273
申请日：2020-02-14
发明人： Micah BENSON , Jason MERKIN , Gregory V. KRYUKOV , Solomon Martin SHENKER , Michael SCHLABACH , Noah TUBO
IPC分类号： C12N15/11 , C12N15/113 , A61K35/17 , C07K14/705 , C07K14/725 , C07K16/32 , C07K16/28 , C12N5/0783 , C12N9/22 , A61P35/04 , A61P35/02 , A61P35/00
摘要： The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.
-
公开(公告)号：US20190284553A1
公开(公告)日：2019-09-19
申请号：US16354102
申请日：2019-03-14
发明人： Micah BENSON , Jason MERKIN , Gregory V. KRYUKOV , Solomon Martin SHENKER , Michael SCHLABACH , Noah TUBO
IPC分类号： C12N15/11 , A61K35/17 , A61P35/00 , A61P35/02 , A61P35/04 , C12N9/22 , C12N15/113 , C12N5/0783 , C07K16/28 , C07K16/32 , C07K14/725 , C07K14/705
摘要： The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.
-
公开(公告)号：US20230277533A1
公开(公告)日：2023-09-07
申请号：US17904159
申请日：2021-02-12
发明人： Andrew Alistair WYLIE , Solomon Martin SHENKER , Pamela Jean SULLIVAN , Frank STEGMEIER , Anne Louise CADZOW , Hanlan LIU , Kerstin Wolf SINKEVICIUS
IPC分类号： A61K31/502 , A61K31/454 , A61K31/519 , A61K31/55 , A61K31/5025 , A61P35/00
CPC分类号： A61K31/502 , A61K31/454 , A61K31/519 , A61K31/55 , A61K31/5025 , A61P35/00
摘要： The present disclosure provides therapeutic combinations comprising (i) a ubiquitin-specific-processing protease 1 (USP1) inhibitor and (ii) a poly ADP-ribose polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid, or polymorph thereof, wherein the USP1 inhibitor comprises (I), (II), or (III), or pharmaceutically acceptable salts, hydrates, solvates, amorphous solids, or polymorphs thereof. The present disclosure is also directed to the use of the combinations to inhibit a USP1 and/or PARP protein and/or to treat a disorder responsive to the inhibition of USP1 and/or PARP proteins and USP1 and/or PARP activity. The combinations of the present disclosure are especially useful for treating cancer.
-
公开(公告)号：US20220110974A1
公开(公告)日：2022-04-14
申请号：US17426059
申请日：2020-01-31
发明人： John CHO , Jason MERKIN , Noah Jacob TUBO , James Martin KABERNA, II , Solomon Martin SHENKER , Kerem Jonatan TUNCEL
IPC分类号： A61K35/17 , C12N15/113 , C12N9/22 , C07K14/705 , C07K14/47 , A61P37/00
摘要： The present disclosure provides methods and compositions related to the modification of Tregs to increase therapeutic efficacy. In some embodiments, Tregs modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance immunosuppressive functions of the immune cells are provided. In some embodiments, Tregs further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating an autoimmune diseases using the modified Tregs described herein are also provided.
-
-
-
-
搜索结果
5 条记录 (耗时 0.02 秒)
